Northstar Select®
Unmatched sensitivity for more treatment opportunities.
50%
Reduction in false negative results1
109%
More actionable CNVs detected
Northstar Select® is a highly sensitive ctDNA liquid biopsy that uses QCT™ technology to guide therapy selection by detecting actionable alterations, even in low tumor fraction samples.
A purpose-built liquid biopsy.
Northstar Select® uncovers treatment opportunities others miss — focused on the genes that matter most for therapy selection.
Why sensitivity matters
Low VAF alterations can be found even in traditionally high-shedding tumors1.
The most sensitive liquid CGP
Northstar Select achieves a 2 to 5x lower limit of detection than other liquid biopsies2.
Proven in a head-to-head study
Northstar Select uncovered 50%+ more clinically actionable alterations1.
Bower, X., et al., JCO 42, 3072-3072(2024).
LOD 95% (limit of detection 95%) is defined as the lowest concentration of an analyte in a sample that can be consistently detected with ≥95% probability. Comparator assays have a LOD 95% that ranges from 0.20% -0.40%.
More answers start here.
